GLPwatch
Effects of GLP-1 on Chronic Heart Failure
NCT02650596 · Unknown status
Last updated 2026-05-28This clinical trial tests the effects of a medication called GLP-1 on people who have chronic heart failure.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 68 people Planned (estimated).
Who can join Ages 18–80 · all sexes
Timeline Started 2016-01 · est. completion 2018-02
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT02650596 ↗
Description as written by the study sponsor.
The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.
Treatments tested
- GLP-1 also known as Liraglutide Drug
Liraglutide were taken daily for 3 months
- Placebo Drug
Placebo were taken daily for 3 months
| Main thing measured | left ventricular ejection fraction measured by 3D echocardiography |
|---|---|
| Sponsor | Shi Yang |
| Conditions studied | Heart Failure |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02650596 ↗